ARTICLE | Clinical News
Brivanib: Phase III data
July 23, 2012 7:00 AM UTC
The double-blind, international Phase III BRISK-FL trial in 1,155 patients with advanced HCC who have not received prior systemic therapy showed that first-line treatment with once-daily 800 mg oral b...